• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
CHEN Xian, GUO Wenjing, YANG Liliang, ZHOU Yuxin, GUO Qinglong. Research progress on the role of heat shock protein 27 in prostate cancer[J]. Journal of China Pharmaceutical University, 2020, 51(6): 731-738. DOI: 10.11665/j.issn.1000-5048.20200613
Citation: CHEN Xian, GUO Wenjing, YANG Liliang, ZHOU Yuxin, GUO Qinglong. Research progress on the role of heat shock protein 27 in prostate cancer[J]. Journal of China Pharmaceutical University, 2020, 51(6): 731-738. DOI: 10.11665/j.issn.1000-5048.20200613
shu

Research progress on the role of heat shock protein 27 in prostate cancer

Funds: This work was supported by the National Natural Science Foundation of China (No.81703550) and Science Foundation for Distinguished Young Scholars of Jiangsu Province (No.BK20170749)
More Information
  • Received Date: April 19, 2020
  • Revised Date: October 13, 2020
    Graphical Abstract
    • Abstract
  • Prostate cancer is one of the most common cancers in adult men. Heat shock proteins (HSPs),as molecular chaperones widely involved in the pathogenesis,diagnosis,treatment and prognosis of various cancers,play crucial biological functions in prostate cancer and it can be considered as valuable biomarkers for cancer therapy, such as prostate-specific membrane antigen. As a member of the heat shock protein family, HSP27 is related to prostate cancer castration resistance,and its expression can promote tumor resistance,invasion and bone metastasis,making prostate cancer more invulnerable to treatments. Therefore,targeting HSP27 in prostate cancer can be perceived as one promising cancer treatment strategy. This article reviews the structure and function of HSP27,and its potential role on castration resistance and targeted therapy in order to provide a new theoretical basis for the clinical treatment of prostate cancer.
    • FullText(HTML)
    • References (62)
  • [1]
    . Trends Biochem Sci，2016，41（4）：311?323.
    [2]
    Saini J，Sharma PK. Clinical，prognostic and therapeutic significance of heat shock proteins in cancer［J］. Curr Drug Targets，2018，19（13）：1478?1490.
    [3]
    Wu JM，Liu TE，Rios Z，et al. Heat shock proteins and cancer［J］. Trends Pharmacol Sci，2017，38（3）：226?256.
    [4]
    DeSantis CE，Lin CC，Mariotto AB，et al. Cancer treatment and survivorship statistics，2014［J］. CA：A Cancer J Clin，2014，64（4）：252?271.
    [5]
    Conteduca V，Jayaram A，Romero-Laorden N，et al. Plasma androgen receptor and docetaxel for metastatic castration-resistant prostate cancer［J］. Eur Urol，2019，75（3）：368?373.
    [6]
    Boumahdi S，de Sauvage FJ. The great escape：tumour cell plasticity in resistance to targeted therapy［J］. Nat Rev Drug Discov，2020，19（1）：39?56.
    [7]
    Hoter，Rizk，Naim. The multiple roles and therapeutic potential of molecular chaperones in prostate cancer［J］. Cancers，2019，11（8）：1194.
    [8]
    Yun CW，Kim HJ，Lim JH，et al. Heat shock proteins：agents of cancer development and therapeutic targets in anti-cancer therapy［J］. Cells，2019，9（1）：60.
    [9]
    Carra S，Alberti S，Arrigo PA，et al. The growing world of small heat shock proteins：from structure to functions［J］. Cell Stress Chaperones，2017，22（4）：601?611.
    [10]
    Katsogiannou M，Ziouziou H，Karaki S，et al. The hallmarks of castration-resistant prostate cancers［J］. Cancer Treat Rev，2015，41（7）：588?597.
    [11]
    Haslbeck M，Weinkauf S，Buchner J. Small heat shock proteins：simplicity meets complexity［J］. J Biol Chem，2019，294（6）：2121?2132.
    [12]
    Jego G，Hazoumé A，Seigneuric R，et al. Targeting heat shock proteins in cancer［J］. Cancer Lett，2013，332（2）：275?285.
    [13]
    Cayado-Gutiérrez N，Moncalero VL，Rosales EM，et al. Downregulation of HSP27 （HSPB1） in MCF-7 human breast cancer cells induces upregulation of PTEN［J］. Cell Stress Chaperones，2013，18（2）：243?249.
    [14]
    Abisambra JF，Blair LJ，Hill SE，et al. Phosphorylation dynamics regulate HSP27-mediated rescue of neuronal plasticity deficits in tau transgenic mice［J］. J Neurosci，2010，30（46）：15374?15382.
    [15]
    Chatterjee S，Burns TF. Targeting heat shock proteins in cancer：a promising therapeutic approach［J］. Int J Mol Sci，2017，18（9）：1978.
    [16]
    Gibert B，Simon S，Dimitrova V，et al. Peptide aptamers：tools to negatively or positively modulate HSPB1（27） function［J］. Philos Trans R Soc Lond B Biol Sci，2013，368（1617）：20120075.
    [17]
    Yu L，Yuan X，Wang D，et al. Selective regulation of p38β protein and signaling by integrin-linked kinase mediates bladder cancer cell migration［J］. Oncogene，2014，33（6）：690?701.
    [18]
    Zhao M，Shen F，Yin YX，et al. Increased expression of heat shock protein 27 correlates with peritoneal metastasis in epithelial ovarian cancer［J］. Reprod Sci，2012，19（7）：748?753.
    [19]
    Thuringer D，Jego G，Wettstein G，et al. Extracellular HSP27 mediates angiogenesis through Toll-like receptor 3［J］. Faseb J，2013，27（10）：4169?4183.
    [20]
    O''''Callaghan-Sunol C，Gabai VL，Sherman MY. Hsp27 modulates p53 signaling and suppresses cellular senescence［J］. Cancer Res，2007，67（24）：11779?11788.
    [21]
    Zhang S，Hu YM，Huang YW，et al. Heat shock protein 27 promotes cell proliferation through activator protein-1 in lung cancer［J］. Oncol Lett，2015，9（6）：2572?2576.
    [22]
    Hu WM，Wang JP，Luo GQ，et al. Proteomics-based analysis of differentially expressed proteins in the CXCR1-knockdown gastric carcinoma MKN45 cell line and its parental cell［J］. Acta Biochim Biophys Sin （Shanghai），2013，45（10）：857?866.
    [23]
    Bruey JM，Ducasse C，Bonniaud P，et al. Hsp27 negatively regulates cell death by interacting with cytochrome C［J］. Nat Cell Biol，2000，2（9）：645?652.
    [24]
    Li JY，Hu WX，Lan Q. The apoptosis-resistance in t-AUCB-treated glioblastoma cells depends on activation of Hsp27［J］. J Neuro-oncol，2012，110（2）：187?194.
    [25]
    Liu CC，Chou KT，Hsu JW，et al. High metabolic rate and stem cell characteristics of esophageal cancer stem-like cells depend on the Hsp27-AKT-HK2 pathway［J］. Int J Cancer，2019，145（8）：2144?2156.
    [26]
    Kostenko S，Moens U. Heat shock protein 27 phosphorylation：kinases，phosphatases，functions and pathology［J］. Cell Mol Life Sci，2009，66（20）：3289?3307.
    [27]
    Dubrez L，Causse S，Borges Bonan N，et al. Heat-shock proteins：chaperoning DNA repair［J］. Oncogene，2020，39（3）：516?529.
    [28]
    Chine VB，Au NPB，Ma CHE. Therapeutic benefits of maintaining mitochondrial integrity and calcium homeostasis by forced expression of Hsp27 in chemotherapy-induced peripheral neuropathy［J］. Neurobiol Dis，2019，130：104492.
    [29]
    Yin CF，Kao SC，Hsu CL，et al. Phosphoproteome analysis reveals dynamic heat shock protein 27 phosphorylation in tanshinone IIA-induced cell death［J］. J Proteome Res，2020，19（4）：1620?1634.
    [30]
    Okuno M，Yasuda I，Adachi S，et al. The significance of phosphorylated heat shock protein 27 on the prognosis of pancreatic cancer［J］. Oncotarget，2016，7（12）：14291?14299.
    [31]
    Guo Y，Ziesch A，Hocke S，et al. Overexpression of heat shock protein 27 （HSP 27） increases gemcitabine sensitivity in pancreatic cancer cells through S-phase arrest and apoptosis［J］. J Cell Mol Med，2015，19（2）：340?350.
    [32]
    Kang DX，Choi HJ，Kang SJ，et al. Ratio of phosphorylated HSP27 to nonphosphorylated HSP27 biphasically Acts as a determinant of cellular fate in gemcitabine-resistant pancreatic cancer cells［J］. Cell Signal，2015，27（4）：807?817.
    [33]
    Fujita K，Nonomura N. Role of androgen receptor in prostate cancer：a review［J］. World J Mens Health，2019，37（3）：288?295.
    [34]
    Cano LQ，Lavery DN，Bevan CL. Mini-review：foldosome regulation of androgen receptor action in prostate cancer［J］. Mol Cell Endocrinol，2013，369（1/2）：52?62.
    [35]
    Zoubeidi A，Zardan A，Beraldi E，et al. Cooperative interactions between androgen receptor （AR） and heat-shock protein 27 facilitate AR transcriptional activity［J］. Cancer Res，2007，67（21）：10455?10465.
    [36]
    Cinar B，Mukhopadhyay NK，Meng GY，et al. Phosphoinositide 3-kinase-independent non-genomic signals transit from the androgen receptor to Akt1 in membrane raft microdomains［J］. J Biol Chem，2007，282（40）：29584?29593.
    [37]
    Ciccarese C，Massari F，Iacovelli R，et al. Prostate cancer heterogeneity：discovering novel molecular targets for therapy［J］. Cancer Treat Rev，2017，54：68?73.
    [38]
    Li J，Fu X，Cao S，et al. Membrane-associated androgen receptor （AR） potentiates its transcriptional activities by activating heat shock protein 27 （HSP27）［J］. J Biol Chem，2018，293（33）：12719?12729.
    [39]
    Kiliccioglu I，Konac E，Dikmen AU，et al. Hsp-27 and NF-κB pathway is associated with AR/AR-V7 expression in prostate cancer cells［J］. Gene，2019，697：138?143.
    [40]
    Zheng G，Zhang Z，Liu H，et al. HSP27-mediated extracellular and intracellular signaling pathways synergistically confer chemoresistance in squamous cell carcinoma of tongue［J］. Clin Cancer Res，2018，24（5）：1163?1175.
    [41]
    Baylot V，Katsogiannou M，Andrieu C，et al. Targeting TCTP as a new therapeutic strategy in castration-resistant prostate cancer［J］. Mol Ther，2012，20（12）：2244?2256.
    [42]
    Azad AA，Zoubeidi A，Gleave ME，et al. Targeting heat shock proteins in metastatic castration-resistant prostate cancer［J］. Nat Rev Urol，2015，12（1）：26?36.
    [43]
    Zoubeidi A，Zardan A，Wiedmann RM，et al. Hsp27 promotes insulin-like growth factor-I survival signaling in prostate cancer via p90Rsk-dependent phosphorylation and inactivation of BAD［J］. Cancer Res，2011，71（14）：5054.
    [44]
    Hayashi N，Peacock JW，Beraldi E，et al. Hsp27 silencing coordinately inhibits proliferation and promotes Fas-induced apoptosis by regulating the PEA-15 molecular switch［J］. Cell Death Differ，2012，19（6）：990?1002.
    [45]
    Aloy MT，Hadchity E，Bionda C，et al. Protective role of Hsp27 protein against gamma radiation-induced apoptosis and radiosensitization effects of Hsp27 gene silencing in different human tumor cells［J］. Int J Radiat Oncol，2008，70（2）：543?553.
    [46]
    Cui Y，Sun Y，Hu S，et al. Neuroendocrine prostate cancer （NEPCa） increased the neighboring PCa chemoresistance via altering the PTHrP/p38/Hsp27/androgen receptor （AR）/p21 signals［J］. Oncogene，2016，35（47）：6065?6076.
    [47]
    Ketteler J，Wittka A，Leonetti D，et al. Caveolin-1 regulates the ASMase/ceramide-mediated radiation response of endothelial cells in the context of tumor-stroma interactions［J］. Cell Death Dis，2020，11（4）：228.
    [48]
    Andrieu C，Taieb D，Baylot V，et al. Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E［J］. Oncogene，2010，29（13）：1883?1896.
    [49]
    Ziouziou H，Andrieu C，Laurini E，et al. Targeting Hsp27/eIF4E interaction with phenazine compound：a promising alternative for castration-resistant prostate cancer treatment［J］. Oncotarget，2017，8（44）：77317?77329.
    [50]
    Voll EA，Ogden IM，Pavese JM，et al. Heat shock protein 27 regulates human prostate cancer cell motility and metastatic progression［J］. Oncotarget，2014，5（9）：2648?2663.
    [51]
    Lee JW，Kwak HJ，Lee JJ，et al. HSP27 regulates cell adhesion and invasion via modulation of focal adhesion kinase and MMP-2 expression［J］. Eur J Cell Biol，2008，87（6）：377?387.
    [52]
    Cordonnier T，Bishop JL，Shiota M，et al. Hsp27 regulates EGF/β-catenin mediated epithelial to mesenchymal transition in prostate cancer［J］. Int J Cancer，2015，136（6）：E496?E507.
    [53]
    Shiota M，Bishop JL，Nip KM，et al. Hsp27 regulates epithelial mesenchymal transition，metastasis，and circulating tumor cells in prostate cancer［J］. Cancer Res，2013，73（10）：3109?3119.
    [54]
    Cho SY，Kang S，Kim DS，et al. HSP27，ALDH6A1 and prohibitin act as a trio-biomarker to predict survival in late metastatic prostate cancer［J］. Anticancer Res，2018，38（11）：6551?6560.
    [55]
    Foster CS，on behalf of the Trans Atlantic Prostate Group，Dodson AR，et al. Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangement［J］. Br J Cancer，2009，101（7）：1137?1144.
    [56]
    Loriot Y，Zoubeidi A，Gleave ME. Targeted therapies in metastatic castration-resistant prostate cancer：beyond the androgen receptor［J］. Urol Clin North Am，2012，39（4）：517?531.
    [57]
    Dong Y，Chen Y，Zhu D，et al. Self-assembly of amphiphilic phospholipid peptide dendrimer-based nanovectors for effective delivery of siRNA therapeutics in prostate cancer therapy［J］. J Control Release，2020，322：416?425.
    [58]
    Kumano M，Furukawa J，Shiota M，et al. Cotargeting stress-activated Hsp27 and autophagy as a combinatorial strategy to amplify endoplasmic reticular stress in prostate cancer［J］. Mol Cancer Ther，2012，11（8）：1661?1671.
    [59]
    Nappi L，Aguda AH，Nakouzi NA，et al. Ivermectin inhibits HSP27 and potentiates efficacy of oncogene targeting in tumor models［J］. J Clin Invest，2020，130（2）：699?714.
    [60]
    Martin PL，Yin JJ，Seng V，et al. Androgen deprivation leads to increased carbohydrate metabolism and hexokinase 2-mediated survival in Pten/Tp53-deficient prostate cancer［J］. Oncogene，2017，36（4）：525?533.
    [61]
    Kim JH，Jung YJ，Choi B，et al. Overcoming HSP27-mediated resistance by altered dimerization of HSP27 using small molecules［J］. Oncotarget，2016，7（33）：53178?53190.
    [62]
    Heinrich JC，Donakonda S，Haupt VJ，et al. New HSP27 inhibitors efficiently suppress drug resistance development in cancer cells［J］. Oncotarget，2016，7（42）：68156?68169.
    • Related Articles

  • Related Articles

    [1]LI Xueyan, CHEN Na, JIANG Cheng. Research progress of KRAS inhibitors[J]. Journal of China Pharmaceutical University, 2024, 55(2): 257-269. DOI: 10.11665/j.issn.1000-5048.2024010801
    [2]YANG Wanwan, YE Fangyu, WU Yujia, WANG Haochen, ZHAO Li. Research progress of PARP inhibitors in cancers and their drug resistance[J]. Journal of China Pharmaceutical University, 2022, 53(5): 525-534. DOI: 10.11665/j.issn.1000-5048.20220503
    [3]YANG Qian, WANG Xiaojian. Research progress of sphingosine kinase 1 inhibitors[J]. Journal of China Pharmaceutical University, 2021, 52(6): 759-768. DOI: 10.11665/j.issn.1000-5048.20210615
    [4]ZHAN Kangning, QUAN Xu, HUANG Zhangjian, ZHAO Liwen. Research progress of protein arginine methyltransferase 5 inhibitors[J]. Journal of China Pharmaceutical University, 2021, 52(3): 371-378. DOI: 10.11665/j.issn.1000-5048.20210315
    [5]LI Zhiyan, LIU Jie, LI Bingyan, JIANG Cheng. Design, synthesis and evaluation of peptidomimetics targeting the polo-box domain of polo-like kinase 1[J]. Journal of China Pharmaceutical University, 2020, 51(3): 287-294. DOI: 10.11665/j.issn.1000-5048.20200305
    [6]LIANG Tingting, WANG Wenjie, HE Guangchao, HE Guangchao, XU Yungen. Research progress of ERK small molecule inhibitors[J]. Journal of China Pharmaceutical University, 2020, 51(3): 260-269. DOI: 10.11665/j.issn.1000-5048.20200302
    [7]SHI Jinyu, BAI Ying, PENG Kewen, ZHANG Wenhui, ZHU Qihua, XU Yungen. Research progress of PARP-1 inhibitors in combination with other drugs to overcome drug resistance[J]. Journal of China Pharmaceutical University, 2019, 50(5): 523-530. DOI: 10.11665/j.issn.1000-5048.20190503
    [8]WANG Tianshuai, YU Junjie, ZHANG Yan, ZENG Jinjin, CUI Jingxin. Advances in platinum-intercalators of DNA as antitumor agents[J]. Journal of China Pharmaceutical University, 2019, 50(5): 505-515. DOI: 10.11665/j.issn.1000-5048.20190501
    [9]GUO Yahui, LU Peng, WANG Yubin, ZHANG Huibin. Progress in the researches for antitumor NEDD8 activating enzyme inhibitors[J]. Journal of China Pharmaceutical University, 2017, 48(6): 646-653. DOI: 10.11665/j.issn.1000-5048.20170603
    [10]KONG Kai-lai, LU Shuai, GAO Yi-ping, YANG Pei, TANG Wei-fang, LU Tao. Advances on the study of PLK1 inhibitors as antitumor agents[J]. Journal of China Pharmaceutical University, 2011, 42(1): 9-15.

Catalog

    Get Citation
    PDF
    XML
    Article views (253) PDF downloads (1134) Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：302646

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return